Erlotinib Impurity 31 | CAS 183320-24-3 - Request Quote
Erlotinib Impurity 31
| SZ CAT No: | SZ-E018048 |
| CAS No | 183320-24-3 |
| Mol.F. | C23H23N3O5 |
| Mol.Wt. | 421.5 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Erlotinib Impurity 31 is chemically 2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl acetate. Erlotinib Impurity 31 is supplied with detailed characterization data compliant with regulatory guideline. Erlotinib Impurity 31 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Erlotinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 183320-24-3
Purchase 183320-24-3
Order 183320-24-3
Enquire 183320-24-3
price of 183320-24-3
183320-24-3 Supplier
183320-24-3 Manufacturer
183320-24-3 Exporter
buy high quality Erlotinib Impurity 31
Purchase Erlotinib Impurity 31
Erlotinib Impurity 31 suppliers
Erlotinib Impurity 31 manufacturers
Erlotinib Impurity 31 price
Order Erlotinib Impurity 31
Enquire Erlotinib Impurity 31
Erlotinib Impurity 31 cost
Erlotinib Impurity 31 Supplier
Erlotinib Impurity 31 Distributor
Erlotinib Impurity 31 for Method Validation
Erlotinib Reference Standard
Erlotinib Impurity 31 for ANDA Filing
Erlotinib Impurity 31 for Forced Degradation Studies
Erlotinib Impurity 31 Identification Standards
Erlotinib Impurity 31 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.